Revolutionary Device Detects Cancer in Just One Hour, Could Transform Healthcare Access

A groundbreaking device developed by researchers at the University of Texas at El Paso (UTEP) promises to revolutionize cancer detection, particularly in resource-limited settings. This portable, low-cost device can identify colorectal and prostate cancer within an hour, offering hope for earlier diagnosis and improved patient outcomes.

Led by Professor XiuJun (James) Li, PhD, a team of researchers created a prototype biochip device that utilizes a unique “paper-in-polymer-pond” structure. Patient blood samples are introduced into tiny wells, allowing cancer protein biomarkers to bind to a specialized paper. Within minutes, the paper changes color, indicating the presence and stage of cancer.

Why This Breakthrough Matters:

Current methods, like ELISA, often rely on expensive instruments and lengthy processing times, sometimes exceeding 12 hours. This poses a significant challenge in rural areas and developing countries, where access to specialized equipment is limited. Delays in diagnosis can be detrimental, hindering early intervention and increasing cancer mortality rates.

Li emphasizes the importance of early detection: “If you can detect biomarkers early on, before the cancer spreads, you increase a patient’s chance of survival. Any delays in testing, especially in regions that don’t have access to expensive tools and instruments, can be very bad for a patient’s prognosis.”

Advantages of the UTEP Device:

• **Low Cost:** Estimated at just a few dollars, making it accessible to a wider population.
• **Rapid Results:** Provides diagnosis within an hour, significantly faster than traditional methods.
• **Portable:** Eliminates the need for specialized instruments, enabling testing in remote locations.
• **Highly Sensitive:** Detects cancer biomarkers at lower concentrations, crucial for early-stage diagnosis.

While promising, the device requires further development and clinical trials before becoming widely available. Li’s team anticipates several years of testing and FDA approval before it reaches patients.

“Dr. XiuJun Li’s innovation significantly improves point-of-care diagnostics by reducing detection times and the need for costly instruments,” said Robert Kirken, dean of the College of Science. “This makes it ideal for resource-limited settings, which will improve early diagnosis and lead to better cancer outcomes. I look forward to seeing what this innovation leads to.”

Li’s research, published in the journal Lab on a Chip, highlights the potential of microfluidic technology to transform healthcare, particularly in underserved communities.

Stay informed about this groundbreaking development and the future of cancer detection. Subscribe to our newsletter for the latest updates!